SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors brace for the highly anticipated 80th event trigger in the REGAL Phase 3 trial, which will unblind the survival data and potentially catalyze a major acquisition. The community is intensely debating the stock's valuation, fueled by speculation regarding a multi-billion dollar buyout from big pharma players and significant upward pressure from elevated short borrow fees.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing renewed investor interest driven by rising trading volume and community debates over its role in Japan's blockchain ecosystem, though skeptics remain focused on past price volatility and concerns regarding long-term utility. Despite polarized sentiment, the community is actively tracking technical support levels and speculating on potential institutional adoption in the IoT and data ownership sectors.

FreeCast, Inc. operates an online video streaming platform. Its cloud entertainment platform comprises the largest aggregated library of free and pay-per-view video-on-demand, streaming channels, live events, radio stations, music videos and online games. The company was founded by William A. Mobley, Jr. on June 21, 2011 and is headquartered in Orlando, FL.

Freecast Inc - Ordinary Shares - Class A

Freecast Inc

Freecast Inc. is experiencing extreme volatility and intense retail interest driven by a strategic reseller agreement with Starlink Business, fueling a massive short squeeze momentum. While retail bulls are aggressively targeting a continued rally and celebrating significant gains, community discourse remains sharply polarized between those betting on further upside potential and skeptics warning of imminent dilution risks and weak fundamentals.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors debate the impact of the company's new C$150 million At-The-Market equity program, with some viewing the dilution as a necessary step to fund R&D while others fear further stock price collapse. The community remains deeply divided, balancing excitement over the company's post-quantum cryptography pilots and hardware development against concerns regarding its lack of revenue and the volatile public feud between company leadership.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense debate as investors weigh the potential of its AI software against technical pressure and concerns about valuation multiples and sector rotation. The community remains deeply divided between long-term bulls who point to accelerating commercial and government contract adoption, and vocal bears who highlight recent technical weaknesses and speculative volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is rallying as investors await critical Phase 3 VELA 52-week clinical data, which many anticipate will confirm the company's leading position in the Hidradenitis Suppurativa market. The community is heavily focused on the potential for a major valuation rerating or acquisition, with discussions centering on whether the upcoming trial results will trigger an M&A event or validate the asset's 'best-in-class' therapeutic potential.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is generating significant market buzz following the announcement of a collaboration with Midjourney to integrate its ultrasound-on-chip technology into AI-powered full-body scanners. While the community is actively debating the stock's long-term potential as a semiconductor player versus the risk of hype-driven volatility, sentiment is split between investors anticipating an epic short squeeze and skeptics warning of a classic sell-the-news event.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense debate among investors as community members weigh the stock's long-term potential in the voice AI sector against concerns over insider share disposals, acquisition-related dilution, and short-seller pressure. While bulls point to recent industry recognition as an AI leader and a growing backlog of enterprise contracts as signs of an impending reversal, others remain skeptical, focusing on the company's path to profitability and lack of immediate catalysts to spark a sustained rally.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing a parabolic, sentiment-driven rally fueled by severe memory and NAND flash supply shortages and increasing demand from data center infrastructure. While bulls are celebrating consistent ATHs and rapid gains, the community is deeply polarized, with many retail traders debating whether the stock is undergoing a historic re-rating or forming a dangerous bubble reminiscent of the dot-com era.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant upward momentum as investors speculate on upcoming FDA peptide reviews and growth from new product integrations. The stock is currently a major focus for retail and institutional traders, with the community actively debating potential short-squeeze mechanics and the company's ability to maintain its recent price breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

John B. Sanfilippo & Son to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th & 11th in New York, NY

John B. Sanfilippo & Son (NASDAQ: JBSS) today announced management will present at the East Coast IDEAS Investor Conference on Thursday June 11, 2026 at The Westin Times Square in New York, NY. The Companys presentation is scheduled to begin at 9:55am ET and will hold investor meetings throughout...

John B. Sanfilippo & Son, Inc. Voluntarily Recalls Snack Mix Products Due to Possible Health Risk

As a follow up to the voluntary recall of dry milk powder by California Dairies, Inc. due to the potential presence of Salmonella, John B. Sanfilippo & Son, Inc. (Nasdaq: JBSS) (the Company) announced today that it is voluntarily recalling certain snack mix items listed below that were flavored...

Wall Street Zen Downgrades John B. Sanfilippo & Son (NASDAQ:JBSS) to Buy

Wall Street Zen cut John B. Sanfilippo & Son from a "strong-buy" rating to a "buy" rating in a research note on Saturday...

John B. Sanfilippo & Son Q3 Earnings Call Highlights

John B. Sanfilippo & Son (NASDAQ:JBSS) reported fiscal third-quarter 2026 results highlighted by record net sales growth driven primarily by higher pricing, while profitability declined year over...

Sanfilippo & Son (JBSS) Q3 Earnings and Revenues Surpass Estimates

John B. Sanfilippo (JBSS) delivered earnings and revenue surprises of +23.70% and +8.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

John B. Sanfilippo & Son (NASDAQ:JBSS) Releases Earnings Results, Beats Estimates By $0.27 EPS

John B. Sanfilippo & Son (NASDAQ:JBSS - Get Free Report) announced its earnings results on Wednesday. The company reported $1.43 EPS for the quarter, beating analysts' consensus estimates of $1.16 by...

John B. Sanfilippo & Son, Inc. Reports Fiscal 2026 Third Quarter Results

John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the Company) today announced financial results for its fiscal 2026 third quarter ended March 26, 2026. Third Quarter Summary Net sales increased $20.9...

John B. Sanfilippo & Son (JBSS) Projected to Post Quarterly Earnings on Wednesday

John B. Sanfilippo & Son (NASDAQ:JBSS) will be releasing its Q3 2026 earnings after the market closes on Wednesday, April 29. (View Earnings Report at...

Lamb Weston (LW) Q3 Earnings and Revenues Top Estimates

Lamb Weston (LW) delivered earnings and revenue surprises of +18.42% and +5.40%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?

John B. Sanfilippo & Son, Inc. Declares $1.50 Per Share Special Dividend

John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the Company) today announced that its Board of Directors (the Board) declared a special cash dividend (the Special Dividend) of $1.50 per share on all...

John B. Sanfilippo & Son, Inc. engages in the processing and distribution of nuts and nut-related products. It offers peanuts, pecans, cashews, walnuts, almonds, and other nuts under the brands of Fisher, Orchard Valley Harvest, Squirrel Brand, and Southern Style Nuts. The company was founded by Gaspare Sanfilippo and John B. Sanfilippo in 1922 and is headquartered in Elgin, IL.

Sanfilippo (John B.) & Son, Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$78.04
Prev Close	$77.65
Open	$78.45
Dividend Yield	1.35%
50-Day Moving Average	$77.63
Beta	0.22
Avg. Volume	114,847.44
PE Ratio	13.68

52-Week High	$84.89
52-Week Low	$57.19
Market Capitalization	$912.04M
EPS (Annual)	$5.03
Price to Book	2.35
Revenue Per Employee	$582,761.05

JBSSSanfilippo (John B.) & Son, Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JBSS News